Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008:2:367-9.
doi: 10.4137/cmo.s677. Epub 2008 Apr 24.

Octreotide in Palliative Treatment of Unresectable Cholangiocarcinoma: Is it Effective for Disease Stabilization?

Kiki Pistevou-Gompaki  1 , Nikos Eleftheriadis, Christos Papaloukas, Damianos Eleftheriadis
Affiliations

Octreotide in Palliative Treatment of Unresectable Cholangiocarcinoma: Is it Effective for Disease Stabilization?

Kiki Pistevou-Gompaki et al. Clin Med Oncol. 2008.
No abstract available

Keywords: Klatskin tumor; cholangiocarcinoma; octreotide LAR; palliative treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time course of VAS and AIS values in pt A after octreotide administration.
Figure 2
Figure 2
Time course of VAS and AIS values in pt B after octreotide administration.
See this image and copyright information in PMC

References

    1. Courtney M, Townsend J. Tumors of the biliary tree. In: Yamada T, Alpers D, Owyang C, Powell Don W, Silverstein FE, editors. Textbook of gastroenterology. second edition, IB. II. Lippincott Company; Philladelphia: 1995. pp. 2254–65.
    1. Shaib YH, Davila JA, Henderson L, McGlynn KA, El-Serag HB. Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study. J. Clin. Gastroenterol. 2007;41(10):911–7. - PubMed
    1. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol. 1997;8:1041–4. - PubMed
    1. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F, Conte PF. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumours. Am J Clin Oncol. 2000;23:412–5. - PubMed
    1. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42:442–7. - PMC - PubMed

LinkOut - more resources